Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambulosono Musical Walking Program and Rasagiline in Parkinson's Disease
NCT02207387Unknown
- Sponsor
- University of British Columbia
- Start
- Oct 2013
- Primary completion
- Mar 2017
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Randomised, open-label trial of rasagiline in Parkinson's disease (PD) (5 arms), sponsored by University of British Columbia. Primary endpoint: Change from baseline in brain imaging signals (fMRI) at 4 months. Status: unknown.
02
Drugs
rasagiline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02207387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02207387.